1SUPPLEMENTARY MATERIALS

2Supplementary table Complications

MedDRA Preferred Term, n (%)a Working Ability Working Ability

Recovered Not Recovered

N = 122 N = 91
Hypertension 2 (1.6) 5 (5.5)
Essential hypertension 1 (0.8) 2 (2.2)
Sleep disorder 0 3 (3.3)
Asthma 1 (0.8) 1 (1.1)
Gastrooesophageal reflux disease 2 (1.6) 0
Panic disorder 2 (1.6) 0
Rheumatoid arthritis 1 (0.8) 1 (1.1)
Anal prolapse 0 1 (1.1)
Anxiety disorder 0 1 (1.1)
Arrhythmia 1 (0.8) 0
Autonomic nervous system imbalance 0 1 (1.1)
Cerebral infarction 0 1 (1.1)
Cervicobrachial syndrome 1 (0.8) 0
Chloasma 0 1 (1.1)
Constipation 0 1 (1.1)
Dermatitis atopic 0 1 (1.1)
Diabetes mellitus 0 1 (1.1)
Dyslipidaemia 0 1 (1.1)
Glaucoma 0 1 (1.1)
Hepatic steatosis 0 1 (1.1)
Ligament rupture 0 1 (1.1)
Menopausal symptoms 1 (0.8) 0
Menstruation irregular 0 1 (1.1)
Migraine 1 (0.8) 0
Rhinitis allergic 0 1 (1.1)
Seasonal allergy 1 (0.8) 0
Sleep apnoea syndrome 0 1 (1.1)
Thyroid neoplasm 0 1 (1.1)
3 MedDRA version 18.1.
a

4If patients had multiple complications, all complications were counted separately.

6Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities.

8 Dec 2020 Page 1 of 9

 7Supplementary Figure 1 Time course of effectiveness outcome measures for the 12-

8week treatment period by working ability. (a) HAM-D17 total score; (b) HAM-D17 core

9score; (c) HAM-D17 insomnia score; (d) HAM-D17 anxiety score; (e) HAM-D17 somatic

10score; (f) BPI-SF; (g) SASS; (h) GAF; (i) EQ-5D.

11Notes: The means and standard deviations are shown for the time points at baseline

12and Weeks 2, 4, 8, and 12. **p<0.01, *p<0.05, comparison between the working ability

13recovered group and the working ability not recovered group using Welch's t-test for

14means of each outcome measure.

15Abbreviations: BPI-SF, Brief Pain Inventory-Short Form; EQ-5D, EuroQol-5

16Dimensions questionnaire for quality of life; GAF, Global Assessment of Functioning;

17HAM-D17, 17-item Hamilton Rating Scale for Depression; SASS, Social Adaptation

18Self-evaluation Scale.

8 Dec 2020 Page 2 of 9

19

8 Dec 2020 Page 3 of 9

20

8 Dec 2020 Page 4 of 9

21

8 Dec 2020 Page 5 of 9

22Supplementary Figure 2 Time course of effectiveness outcome measures for the 12-

23week treatment period between groups by working ability and depressive episodes. (a)

24HAM-D17 total score; (b) HAM-D17 core score; (c) HAM-D17 insomnia score; (d)

25HAM-D17 anxiety score; (e) HAM-D17 somatic score; (f) BPI-SF; (g) SASS; (h) GAF;

26(i) EQ-5D.

27Notes: The means and standard deviations are shown for the time points at baseline

28and Weeks 2, 4, 8, and 12. **p<0.01, *p<0.05, comparison between groups by working

29ability and depressive episodes using Welch's t-test for means of each outcome

30measure.

31Abbreviations: BPI-SF, Brief Pain Inventory-Short Form; EQ-5D, EuroQol-5

32Dimensions questionnaire for quality of life; GAF, Global Assessment of Functioning;

33HAM-D17, 17-item Hamilton Rating Scale for Depression; SASS, Social Adaptation

34Self-evaluation Scale.

8 Dec 2020 Page 6 of 9

35

8 Dec 2020 Page 7 of 9

36

8 Dec 2020 Page 8 of 9

37

8 Dec 2020 Page 9 of 9